Conclusions
fractures
In a randomized, blinded, and controlled noninferiority clinical trial, we have found that there was no significant difference in the safety and performance outcomes between the TFNA and PFNA-II devices investigated in this study. It can therefore be concluded that the TFNA is as efficacious and safe as the PFNA-II product to treat fractures of the proximal femur and femoral shaft.